Drug Profile
Research programme: pancreatic cancer vaccine - Astrimmune
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Astrimmune
- Developer Astrimmune; London Genetics
- Class Cancer vaccines
- Mechanism of Action Gastrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pancreatic cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Pancreatic-cancer in United Kingdom
- 15 Nov 2010 Early research in Pancreatic cancer in United Kingdom (unspecified route)